FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

2 ALS Drugs Miss Endpoints

Denali Therapeutics and Calico Life Sciences say their two eukaryotic initiation factor 2B activator drugs each failed to meet primary and secondary e...

latest-news-card-1
Medical Devices

Lifecycle Recommendations for AI-Enabled Devices

FDA publishes a draft guidance with recommendations on lifecycle management and marketing submissions for AI-enabled medical device software functions...

latest-news-card-1

Sex Differences in Clinical Evaluations of Products

FDA publishes a draft guidance intended to improve the representation of females in medical product clinical trials.

Biologics

RSV Vaccines Get Guillain-Barr Warning

FDA requires safety labeling changes about Guillain-Barr syndrome risks for Pfizers Abrysvo (respiratory syncytial virus vaccine) and GlaxoSmithKline ...

latest-news-card-1
Human Drugs

Optical Imaging Drug Development Guidance

FDA publishes a draft guidance on developing drugs for optical imaging for three purposes.

latest-news-card-1
Human Drugs

Dizal Lung Cancer NDA Accepted for Priority Review

FDA accepts for priority review a Dizal NDA for sunvozertinib, an oral EGFR inhibitor for treating locally advanced or metastatic non-small cell lung ...

latest-news-card-1
Human Drugs

Guide on Clinical Trials Using Tissue Biopsies

FDA posts a draft guidance entitled Considerations for Including Tissue Biopsies in Clinical Trials.

latest-news-card-1
Human Drugs

Draft Guide on Using AI for Drug Development

FDA releases a draft guidance entitled Considerations for the Use of Artificial Intelligence (AI) to Support Regulatory Decision-Making for Drug and B...

latest-news-card-1
Human Drugs

Neumoras Phase 3 Depression Study Misses Endpoints

Neumora Therapeutics says its Phase 3 KOASTAL-1 Study of navacaprant for treating major depressive disorder missed its primary endpoint and a key seco...

latest-news-card-1
Human Drugs

CDER Approved 50 Novel Products Last Year

CDER approves 50 novel products in 2024, five less than the 55 products approved in 2023 and well above the 10-year rolling annual average of 46 appro...